Dib FS, González JY, Leal OSE, Galván SG

Language: Spanish
References: 16
Page: 192-197
PDF size: 518.66 Kb.

ABSTRACT

Dermatomyositis is an idiopathic disease that belongs to the group of inflammatory myopathies. The presence of characteristic skin lesions is the inherent quality of this pathology and depending on the degree of muscular involvement it can be classified as amyopathic or myopathic. All the clinical variants of this entity have a high risk of malignancy, so it is estimated that up to 30% of all the cases of dermatomyositis that debut in adulthood are presented as a paraneoplastic syndrome; in which the response or evolution of the cutaneous and muscular pathology will depend on the control or activity of the underlying oncological disease. We report the clinical cases of two patients with history of cancer, in whom dermatomyositis was diagnosed as a paraneoplastic syndrome, one of them with muscular involvement and the other without it.

REFERENCES

1. Mainetti C, Terziroli B y Selmi C, Cutaneous manifestations of dermatomyositis: a comprehensive review, Clin Rev Allergy Immunol 2017; 53(3):0337-56.

2. Caproni M, Cardinali C, Parodi A, Giomi B, Papini M, Vaccaro M et al., Amyopathic dermatomyositis, Arch Dermatol 2002; 138(1):23-7.

3. Wolff M, Mancuso C, Lal K, Dicostanzo D y Gropper C, Paraneoplastic dermatomyositis with cutaneous and myopathic disease responsive to adrenocorticotropic hormone therapy, J Clin Aesthet Dermatol 2017; 10(1):57-62.

4. Udkof J y Cohen PR, Amyopathic dermatomyositis: a concise review of clinical manifestations and associated malignancies, Am J Clin Dermatol 2016; 17(5):509-18.

5. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Ario A et al., Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study, Lancet 2001; 357(9250):96-100.

6. Hendren E, Vinik O, Faragalla H y Haq R, Breast cancer and dermatomyositis: a case study and literature review, Curr Oncol 2017; 24(5):e429-e33.

7. Femia AN, Vleugels RA y Callen JP, Cutaneous dermatomyositis: an updated review of treatment options and internal associations, Am J Clin Dermatol 2013; 14(4):291-313.

8. Mandel DE, Malemud CJ y Askari AD, Idiophatic inflammatory myopathies: a review of the classification and impact of pathogenesis, Int J Mol Sci 2017; 18(5):1084-93.

9. Sasaki H y Kohsaka H, Current diagnosis and treatment of polymyositis and dermatomyositis, Mod Rheumatol 2018; 28(6):913-21.

10. Hoesly P, Sluzevich JC, Jambusaria-Pahlajani A, Lesser ER, Heckman MG, Abril A et al., Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis, J Am Acad Dermatol 2018; Epub ahead of print: S0190-9622(18)32913-X.

11. Galimberti F, Li Y y Fernández AP, “Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancyassociated risk factors in a specific tertiary-care-centre cohort, Br J Dermatol 2016; 174(1):158-64.

12. Ghazi E, Sontheimer RD y Werth VP, The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum, Clin Exp Rheumatol 2012; 31(1):128-34.

13. Marvi U, Chung L y Fiorentino DF, Clinical presentation and evaluation of dermatomyositis, Indian J Dermatol 2012; 57(5):375-81.

14. Dalakas MC, Inflammatory muscle diseases, N Eng J Med 2015; 372(18):1734-47.

15. Iorizzo LJ y Jorizzo JL, The treatment and prognosis of dermatomyositis: an updated review, J Am Acad Dermatol 2008; 59(1):99-112.

16. Bronner IM, Van der Meulen MF, De Visser M, Kalmijn S, Van Vebrooij WJ, Voskuyl AE et al., Long-term outcome in polymyositis and dermatomyositis, Ann Rheum Dis 2006; 65:1456-61.